2024-03-28T22:51:36Z
https://tsukuba.repo.nii.ac.jp/oai
oai:tsukuba.repo.nii.ac.jp:00053277
2022-04-27T09:27:08Z
2780:1781
2780:2204
3:62:5591:7553
Particle therapy for prostate cancer: The past, present and future
石川, 仁
イシカワ, ヒトシ
ISHIKAWA, Hitoshi
櫻井, 英幸
サクライ, ヒデユキ
SAKURAI, Hideyuki
Tsuji, Hiroshi
Murayama, Shigeyuki
Sugimoto, Mikio
Shinohara, Nobuo
Maruyama, Satoru
Murakami, Motohiro
Shirato, Hiroki
Although prostate cancer control using radiotherapy is dose‐dependent, dose–volume effects on late toxicities in organs at risk, such as the rectum and bladder, have been observed. Both protons and carbon ions offer advantageous physical properties for radiotherapy, and create favorable dose distributions using fewer portals compared with photon‐based radiotherapy. Thus, particle beam therapy using protons and carbon ions theoretically seems suitable for dose escalation and reduced risk of toxicity. However, it is difficult to evaluate the superiority of particle beam radiotherapy over photon beam radiotherapy for prostate cancer, as no clinical trials have directly compared the outcomes between the two types of therapy due to the limited number of facilities using particle beam therapy. The Japanese Society for Radiation Oncology organized a joint effort among research groups to establish standardized treatment policies and indications for particle beam therapy according to disease, and multicenter prospective studies have been planned for several common cancers. Clinical trials of proton beam therapy for intermediate‐risk prostate cancer and carbon‐ion therapy for high‐risk prostate cancer have already begun. As particle beam therapy for prostate cancer is covered by the Japanese national health insurance system as of April 2018, and the number of facilities practicing particle beam therapy has increased recently, the number of prostate cancer patients treated with particle beam therapy in Japan is expected to increase drastically. Here, we review the results from studies of particle beam therapy for prostate cancer and discuss future developments in this field.
journal article
WILEY
2019-07
application/pdf
International journal of urology
10
26
971
979
0919-8172
AA11042471
https://tsukuba.repo.nii.ac.jp/record/53277/files/IJU_26-10.pdf
eng
31284326
10.1111/iju.14041
© 2019 The Authors. International Journal of Urology published by John Wiley & Sons Australia, Ltd on behalf of the Japanese Urological Association.
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDe rivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is noncommercial and no modifications or adaptations are made.